Direct Oral Anticoagulants (DOACs) | 合法醫療器材資訊網

Theyareconsideredtobeatleastaseffectiveaswarfarin.Availablemedicationsinthiscategoryincludeapixaban(Eliquis®),betrixaban(BevyxXa®),dabigatran(​ ...

Several direct oral anticoagulants (DOACs) have been approved by the United States Food & Drug Administration (FDA) since 2010. Unlike warfarin these drugs do not require regular blood monitoring. These medications directly inhibit the blood’s ability to form blood clots.

DOACs are both rapid and short-acting agents with relatively low bleeding risks and good overall safety profiles. They are considered to be at least as effective as warfarin. Available medications in this category include apixaban (Eliquis®), betrixaban (BevyxXa®), dabigatran (Pradaxa®), edoxaban (Savaysa®) and rivaroxaban (Xarelto®). Others are in various stages of clinical study.

DOACs are an alternative choice for blood clot treatment in appropriately selected patients. Unlike warfarin, DOACs do not require regular laboratory monitoring and are not affected by food or alcohol. However, DOACs tend ...